DECISION

 

Allergan, Inc. v. Sat Sat / Allergan Singapore Pte Ltd

Claim Number: FA2601002197886

 

PARTIES

Complainant is Allergan, Inc. ("Complainant"), United States, represented by Molly Buck Richard of Richard Law Group, Inc., United States. Respondent is Sat Sat / Allergan Singapore Pte Ltd ("Respondent"), Myanmar.

 

REGISTRAR AND DISPUTED DOMAIN NAME

The domain name at issue is <allerganaesthetics-sg.com>, registered with NameCheap, Inc.

 

PANEL

The undersigned certifies that he has acted independently and impartially and to the best of his knowledge has no known conflict in serving as Panelist in this proceeding.

 

David E. Sorkin as Panelist.

 

PROCEDURAL HISTORY

Complainant submitted a Complaint to Forum electronically on January 5, 2026; Forum received payment on January 5, 2026.

 

On January 6, 2026, NameCheap, Inc. confirmed by email to Forum that the <allerganaesthetics-sg.com> domain name is registered with NameCheap, Inc. and that Respondent is the current registrant of the name. NameCheap, Inc. has verified that Respondent is bound by the NameCheap, Inc. registration agreement and has thereby agreed to resolve domain disputes brought by third parties in accordance with ICANN's Uniform Domain Name Dispute Resolution Policy (the "Policy").

 

On January 7, 2026, Forum served the Complaint and all Annexes, including a Written Notice of the Complaint, setting a deadline of January 27, 2026 by which Respondent could file a Response to the Complaint, via email to all entities and persons listed on Respondent's registration as technical, administrative, and billing contacts, and to postmaster@allerganaesthetics-sg.com. Also on January 7, 2026, the Written Notice of the Complaint, notifying Respondent of the email addresses served and the deadline for a Response, was transmitted to Respondent via post and fax, to all entities and persons listed on Respondent's registration as technical, administrative, and billing contacts.

 

Having received no response from Respondent, Forum transmitted to the parties a Notification of Respondent Default.

 

On January 28, 2026, pursuant to Complainant's request to have the dispute decided by a single-member Panel, Forum appointed David E. Sorkin as Panelist.

 

Having reviewed the communications records, the Administrative Panel (the "Panel") finds that Forum has discharged its responsibility under Paragraph 2(a) of the Rules for Uniform Domain Name Dispute Resolution Policy (the "Rules") "to employ reasonably available means calculated to achieve actual notice to Respondent" through submission of Electronic and Written Notices, as defined in Rule 1 and Rule 2. Therefore, the Panel may issue its decision based on the documents submitted and in accordance with the ICANN Policy, ICANN Rules, Forum's Supplemental Rules, and any rules and principles of law that the Panel deems applicable, without the benefit of any response from Respondent.

 

RELIEF SOUGHT

Complainant requests that the domain name be transferred from Respondent to Complainant.

 

PRELIMINARY ISSUE: IDENTITY THEFT - REQUEST FOR REDACTION

Complainant contends that the organization name supplied by Respondent is false and requests that it be redacted from the decision pursuant to Supplemental Rule 15(b). Complainant acknowledges the existence of an entity by the name "Allergan Singapore Pte Ltd" but states that it is located in Singapore, not Myanmar, and is not connected with Respondent. The Panel acknowledges the likely falsity of the information, but finds no exceptional circumstances present in this matter that warrant redaction.

 

PARTIES' CONTENTIONS

A. Complainant

Complainant is a pharmaceutical company that markets its products in around 100 countries worldwide. Complainant has used ALLERGAN and ALLERGAN AESTHETICS in connection with pharmaceutical preparations and substances for many years. Complainant owns longstanding trademark registrations for ALLERGAN in standard character form in the United States, Myanmar, and many other jurisdictions worldwide, and for ALLERGAN AESTHETICS in standard character form in the United States and other jurisdictions.

 

The disputed domain name <allerganaesthetics-sg.com> was registered in June 2025. The name is registered in the name of a privacy registration service on behalf of Respondent. The domain name is currently being used to redirect to Complainant's official website at <allerganaesthetics.com>. Complainant states that there are active MX records associated with the domain name, suggesting that Respondent may be using it to impersonate Complainant in email communications. Complainant states that Respondent is not commonly known by the domain name, is not affiliated with Complainant, and is not licensed to use Complainant's marks.

 

Complainant contends on the above grounds that the disputed domain name <allerganaesthetics-sg.com> is confusingly similar to its ALLERGAN and ALLERGAN AESTHETICS marks; that Respondent lacks rights or legitimate interests in the disputed domain name; and that the disputed domain name was registered and is being used in bad faith.

 

B. Respondent

Respondent failed to submit a Response in this proceeding.

 

FINDINGS

The Panel finds that the disputed domain name is confusingly similar to a mark in which Complainant has rights; that Respondent lacks rights or legitimate interests in respect of the disputed domain name; and that the disputed domain name was registered and is being used in bad faith.

 

DISCUSSION

Paragraph 15(a) of the Rules instructs this Panel to "decide a complaint on the basis of the statements and documents submitted and in accordance with the Policy, these Rules and any rules and principles of law that it deems applicable."

 

Paragraph 4(a) of the Policy requires that Complainant must prove each of the following three elements to obtain an order that a domain name should be cancelled or transferred:

 

(1)       the domain name registered by Respondent is identical or confusingly similar to a trademark or service mark in which Complainant has rights; and

(2)       Respondent has no rights or legitimate interests in respect of the domain name; and

(3)       the domain name has been registered and is being used in bad faith.

 

In view of Respondent's failure to submit a response, the Panel shall decide this administrative proceeding on the basis of Complainant's undisputed representations pursuant to paragraphs 5(f), 14(a), and 15(a) of the Rules and draw such inferences it considers appropriate pursuant to paragraph 14(b) of the Rules. The Panel is entitled to accept all reasonable allegations set forth in a complaint; however, the Panel may deny relief where a complaint contains mere conclusory or unsubstantiated arguments. See WIPO Overview of WIPO Panel Views on Selected UDRP Questions, § 4.3 (3d ed. 2017), available at http://www.wipo.int/amc/en/domains/search/overview3.0/; UDRP Perspectives on Recent Jurisprudence, §§ 0.2, 0.8 (updated June 2, 2025), available at https://udrpperspectives.org/; see also eGalaxy Multimedia Inc. v. ON HOLD By Owner Ready To Expire, FA 157287 (Forum June 26, 2003) (dismissing complaint where complainant failed to "produce clear evidence to support its subjective allegations").

 

Identical and/or Confusingly Similar

The disputed domain name <allerganaesthetics-sg.com> incorporates Complainant's registered ALLERGAN AESTHETICS trademark, omitting the space and adding a hyphen, the geographic abbreviation "SG," and the ".com" top-level domain. These alterations do not substantially diminish the similarity between the domain name and Complainant's mark. See, e.g., AbbVie Inc. v. Austin Podowski, FA 2079659 (Forum Feb. 9, 2024) (finding <allerganaesthetic.com> confusingly similar to ALLERGAN); Las Vegas Sands Corp. v. wendik ace, FA 1991444 (Forum May 9, 2022) (finding <marinabaysands-sg.com> confusingly similar to MARINA BAY SANDS). The Panel considers the disputed domain name to be confusingly similar to a mark in which Complainant has rights.

 

Rights or Legitimate Interests

Under the Policy, the Complainant must first make a prima facie case that the Respondent lacks rights and legitimate interests in the disputed domain name, and then the burden shifts to the Respondent to come forward with concrete evidence of such rights or legitimate interests. See Hanna-Barbera Productions, Inc. v. Entertainment Commentaries, FA 741828 (Forum Aug. 18, 2006).

 

The disputed domain name incorporates Complainant's registered mark without authorization. Its sole apparent use has been to redirect Internet users to Complainant's website without Complainant's consent. Such use does not give rise to rights or legitimate interests under the Policy. See, e.g., Anschutz Entertainment Group, Inc. v. Faheel Kamran, FA 2160528 (Forum July 11, 2025) (finding lack of rights or interests in similar circumstances); AbbVie Inc. v. Roberto Guerrero, FA 2084014 (Forum Mar. 8, 2024) (same).

 

Complainant has made a prima facie case that Respondent lacks rights and legitimate interests in the domain name, and Respondent has failed to come forward with any evidence of such rights or interests. Accordingly, the Panel finds that Complainant has sustained its burden of proving that Respondent lacks rights or legitimate interests in respect of the disputed domain name.

 

Registration and Use in Bad Faith

Finally, Complainant must show that the disputed domain name was registered and is being used in bad faith. Under paragraph 4(b)(iii) of the Policy, bad faith may be shown by evidence that Respondent registered the disputed domain name "primarily for the purpose of disrupting the business of a competitor." Under paragraph 4(b)(iv), bad faith may be shown by evidence that "by using the domain name, [Respondent] intentionally attempted to attract, for commercial gain, Internet users to [Respondent's] web site or other on-line location, by creating a likelihood of confusion with the complainant's mark as to the source, sponsorship, affiliation, or endorsement of [Respondent's] web site or location or of a product or service on [Respondent's] web site or location."

 

Respondent used a privacy registration service and at least partially fictitious underlying registration information to register a domain name incorporating Complainant's registered mark. The sole apparent use of the domain name has been to redirect Internet users to Complainant's website without Complainant's consent. Respondent has not come forward to offer any explanation for the selection or intended use of the domain name. Under the circumstances, the Panel considers it reasonable to infer that the domain name was registered and is being used to create and exploit confusion with Complainant's mark for commercial gain, perhaps in connection with a phishing scheme. See, e.g., Anschutz Entertainment Group, Inc. v. Faheel Kamran, supra (finding bad faith registration and use in similar circumstances); AbbVie Inc. v. Roberto Guerrero, supra (same). The Panel finds that the disputed domain name was registered and is being used in bad faith.

 

DECISION

Having considered the three elements required under the ICANN Policy, the Panel concludes that relief shall be GRANTED.

 

Accordingly, it is Ordered that the <allerganaesthetics-sg.com> domain name be TRANSFERRED from Respondent to Complainant.

 

 

 

David E. Sorkin, Panelist

Dated: January 28, 2026